- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01271400
LANDA Embryo Freezing Technique. (Freezing)
Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates
Study Overview
Status
Detailed Description
Over the past several decades, considerable effort has been expended toward the successful cryopreservation of various human cells. While attempts at cryopreservation have been directed at different tissue types, one of the most vigorously pursued targets has been reproductive tissue. Historically, cryopreservation of human sperm has existed for several decades. The earliest reports of pregnancies (Trounson et al., 1983) and births (Zeilmaker et al., 1984) from the cryopreservation of human embryos occurred in the early 1980s. Presently, the freezing and storage of human embryos following in vitro fertilization (IVF) is standard practice at most fertility clinics. In 2003, the CDC Assisted Reproductive Technology success rates report stated that 4,246 live births occurred out of 17,517 non-donor frozen embryo cycles.
Embryo cryopreservation has been a routine component of clinical IVF programs for more than 2 decades but has a relatively poor outcome in terms of post-thaw survival and pregnancy rates in a majority of IVF programs. Efficient embryo cryopreservation has several advantages. It helps to reduce costs and increases cumulative pregnancy rates. It can also help in cases of IVF cycles where embryos are not transferred due to ovarian hyper stimulation syndrome. It is also useful when technical difficulties are encountered at the time of an embryo transfer procedure.
One of the major concerns in IVF is high-order multiple pregnancies, which result from the transfer of multiple embryos in a given cycle. In the last 5 years, improved stimulation protocols, advances in culture and laboratory systems, and better identification of viable embryos have enhanced the success rates of IVF. During the same period, some clinics have started the practice of transferring two embryos to reduce multiple pregnancy rates without compromising overall pregnancy rates.
Furthermore, in recent years some European countries, particularly the Scandinavian countries, have taken a lead in performing elective single-embryo transfers and have achieved acceptable pregnancy rates. This trend is spreading to other countries. This can result in surplus embryos being available for freezing. With the application of ICSI, even patients aged 40 years or older may have embryos to freeze.
Review of the current literature reveals modest post-thaw embryo survival, implantation, and pregnancy rates. Post-thaw survival rates vary from 50% to 80% for different embryo stages. Implantation and pregnancy rates have varied from 3% to 15% and 15% to 25% respectively, which is approximately half of the rates achieved for fresh embryo transfers.
To improve the outcome of frozen ET cycles, we modified various steps of our standard cryopreservation protocol. In a pilot study on arrested and fragmented embryos (grades 3 and 4), we achieved post-thaw survival rates of 92%, having all blastomeres intact. Encouraged by the post-thaw survival of these embryos; we propose using this modified protocol in our frozen embryo transfer program.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
California
-
Fountain Valley, California, United States, 92708
- West Coast Fertility Centers
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
To be eligible for inclusion into this study, each subject must satisfy the following criteria:
- Infertile women whose physician has recommended IVF and who agree to cryopreserve surplus embryos.
- Cancer patients who wish to preserve their fertility prior to cancer treatments.
- Recipients who wish to use frozen donor embryos.
- A male partner whose semen analysis meets the clinic criteria for ICSI. Use of donor sperm is also acceptable.
- Be willing and able to comply with the protocol for the duration of the study.
- Have voluntarily provided written informed consent under WIRB.
Exclusion Criteria:
A patient may NOT be entered into the study if she presents with ANY of the following criteria:
- Clinically significant systemic disease.
- Known endometriosis Grade III - IV (ASRM classification).
- Any previous cycle indicating a low response to gonadotropin stimulation (defined as retrieval of < 10 eggs at retrieval)
- Three or more previous ART cycles without a clinical pregnancy
- Abnormal, undiagnosed, gynecological bleeding.
- Previous ovarian surgery
- Known allergy or hypersensitivity to recombinant gonadotropin preparations or any other study-related medications.
- Verifiable substance abuse.
- Simultaneous participation in another study protocol.
- Current smoker.
- An extrauterine pregnancy within the last 3 months before OCP treatment commences.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freeze/Thawed survival rates
Time Frame: When embryos thawed initiate
|
|
When embryos thawed initiate
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David G. Diaz, M.D., West Coast Fertility Centers
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genital Diseases, Female
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...CompletedFemale Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III StatusItaly
-
Arizona State UniversityCatholic Charities Phoenix; Phoenix International Refugee Committee; Refugee... and other collaboratorsCompletedFemale Genital Mutilation Type I Status | Female Genital Mutilation Type II Status | Female Genital Mutilation Type III StatusUnited States
-
The University of Texas Medical Branch, GalvestonM.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaboratorsActive, not recruitingMalignant Neoplasms of Female Genital OrgansUnited States
-
Northwestern UniversityCompletedMalignant Female Reproductive System NeoplasmUnited States
-
Genewel Co., LtdUnknownGenital Diseases, FemaleKorea, Republic of
-
M.D. Anderson Cancer CenterCompletedMalignant Female Reproductive System NeoplasmUnited States
-
Nadezhda Women's Health HospitalMedical diagnostic laboratory ImunoVitaRecruitingFemale InfertilityBulgaria
-
Alexandria UniversityCompleted
-
Alexandria UniversityCompletedFemale InfertilityEgypt
-
Istituto Clinico HumanitasIRCCS San RaffaeleCompleted